| Ticker Symbol: | DYAX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 300 Technology Square Cambridge MA 02139 617 225-2500 |
| CEO/President: | Henry E. Blair |
| Industry: | Medical - Biomedical / Standard Industry Code: 8731 |
| Description: | Dyax Corp is a biopharmaceutical company that has developed and patented a method that is used to identify a broad range of compounds with potential for the treatment and diagnosis of diseases. The company is also using this method to identify compounds that could be used in purifying andmanufacturing biopharmaceuticals and other chemicals. The company\'s phage display technology to rapidly and cost-effectively determine the potential medical uses of newly discovered proteins and genes and subsequently discover biopharmaceutical product candidates. |
| Shares Outstanding: | 60,650 (000) | Market Value: | 200,130 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 64.29% | Number of Inst.Shareholders: | 9.45% |
| Last Quarter Sales: | 5.49 ($Mil.) | Last Quarter Net Income: | -26.64 ($Mil.) |
| Last Quarter EPS: | -0.29 | P/E Ratio: | 0 |
| Most Recent Earnings: | -0.36 on 04/25/02 | Earnings Per Share: | -1.24 |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +5.10 | 55.47 | |
| GILEAD SCIENCES | -8.10 | 44.45 | |
| CELGENE CP | -16.20 | 55.97 | |
| BIOGEN IDEC INC | -30.20 | 44.26 | |
| GENENTECH INC | +4.70 | 80.36 |
